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2 
Abstract 
 
 
IMPORTANCE: The value of the intrinsic subtypes of breast cancer (Luminal A, Luminal 
B, human epidermal growth factor receptor 2 [HER2]-enriched and Basal-like) in the 
metastatic setting is currently unknown. 
 
OBJECTIVE: To evaluate the ability of the intrinsic subtypes of breast cancer to predict 
outcome and/or benefit in hormone receptor (HR)-positive metastatic breast cancer. 
 
DESIGN: Unplanned retrospective analysis of 821 tumor samples (85.7% primary and 
14.3% metastatic) from EGF30008 phase III clinical trial (NCT00073528), where patients 
with HR+ metastatic disease were randomized to letrozole with or without lapatinib, an 
epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor. Tumor samples 
were classified into each subtype using the research-based PAM50 classifier. 
 
SETTING: HR+ metastatic disease with no prior systemic therapy for advanced 
or metastatic disease. 
 
PARTICIPANTS: Postmenopausal women with HR-positive invasive breast cancer and 
no prior therapy for advanced or metastatic disease. Prior neoadjuvant/adjuvant 
antiestrogen therapy was allowed. Patients with extensive symptomatic visceral disease 
were excluded. 
 
MAIN OUTCOMES AND MEASURES: Primary and secondary endpoints were 
progression-free survival and overall survival. Treatment effects were evaluated using 
 
interaction tests. 
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RESULTS: Intrinsic subtype was the strongest prognostic factor independently associated 
with progression-free survival and overall survival in all patients, and in patients with 
HER2-negative (n=644) or HER2+ (n=157) diseases. Median progression-free survival and 
overall survival for each subtype within clinically HER2-negative disease were: Luminal A 
(16.9 and 45.0 months), Luminal B (11.0 and 37.0 months), HER2-enriched (4.7 and 16.0 
months) and Basal-like (4.1 and 23.0 months). Patients with HER2-negative/HER2-
enriched disease benefited from lapatinib (6.5 vs 2.6 months; progression-free survival 
hazard ratio=0.24, 95% confidence interval: 0.07–0.86; interaction P=0.02). 
 
CONCLUSIONS AND RELEVANCE: This is the first study to reveal that the intrinsic 
subtypes are strongly prognostic in first-line HR-positive metastatic disease. HR-
positive/HER2- disease with a HER2-enriched profile may benefit from lapatinib in 
combination with endocrine therapy. The clinical value of intrinsic subtyping in hormone 
receptor-positive metastatic breast cancer warrants further investigation, but patients with 
Luminal A/HER2-negative metastatic breast cancer disease might be good candidates for 
letrozole monotherapy in the first-line setting regardless of visceral disease and number 
of metastases. 
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Introduction 
 
 
Hormone receptor-positive (HR+) metastatic breast cancer consists of a clinically 
heterogeneous group of tumors with different prognoses and responses to endocrine and 
chemotherapy.
1,2
 Except for human epidermal growth factor receptor 2 (HER2) status, 
little is known about its biological heterogeneity and impact on patient outcome. This is 
important since biomarkers that help make treatment decisions in this particular setting are 
urgently needed.
3
 The best treatment approach (ie, endocrine therapy vs chemotherapy) in 
the first-line setting of HR+/HER2-negative disease is unknown and the decision today is 
based on patient characteristics (eg, age), tumor load (eg, number of metastases), type of 
metastasis (visceral vs bone-only) and prior therapy.
3
 
 
In contrast to metastatic disease, much effort has been made to elucidate the biological 
heterogeneity of early breast cancer.
4,5
 During the last 15 years, studies evaluating global gene 
expression patterns have identified four main intrinsic molecular subtypes of breast cancer 
(Luminal A, Luminal B, HER2-enriched [HER2E] and Basal-like).
6-8
 These entities are 
associated with distant recurrence and response to endocrine and chemotherapy, even within 
HR+ disease.
6,7,9
 In fact, patients that have clinically HR+/HER2-negative disease 
 
with a HER2E gene expression profile (which represents 5% of cases) do not seem to 
respond substantially, as estimated by Ki67 changes, from neoadjuvant endocrine 
therapy.
10,11
 Although intrinsic profiles are mostly maintained during metastatic 
progression,
12
 their prognostic and predictive value in patients with newly diagnosed 
HR+ metastatic disease remains largely unknown. 
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Despite recent advances in the treatment of HR+ metastatic breast cancer, resistance to 
endocrine therapies limits their success,
13
 Cross-talk between pathways involving the 
epidermal growth factor family of receptors, epidermal growth factor receptor (EGFR) and 
HER2, and HRs has been implicated in resistance to endocrine therapy.
2,14
 Lapatinib, a dual 
tyrosine kinase inhibitor of EGFR and HER2, has improved response rate and progression-free 
survival (PFS) in first-line HR+ breast cancer in combination with letrozole in patients with 
HER2+ disease (8.2 vs 3.0 months) but not in those with HER2-negative disease.
15
 
 
However, whether patients with HR+/HER2-negative disease but with a HER2E gene 
expression profile benefit from adding lapatinib to endocrine therapy is currently unknown. 
 
Here we evaluated, for the first-time, the prognostic and predictive abilities of intrinsic 
subtypes in tumor samples from EGF30008, a Phase III randomized clinical trial of 
endocrine therapy with or without lapatinib in the first-line metastatic setting.
15
 
 
Materials and Methods 
 
 
Patient data 
 
 
The eligibility criteria and study design for EGF30008 (NCT00073528) were reported 
previously.
15,16
 Briefly, 1286 patients with advanced postmenopausal HR+ breast cancer 
(Stage III or IV) previously untreated in the metastatic setting were randomized in a blinded 
fashion to receive letrozole 2.5 mg daily with either lapatinib 1500 mg daily or placebo. 
Patients were stratified by sites of disease (soft tissue/visceral or bone-only disease) and 
prior adjuvant antiestrogen therapy (<6 months since discontinuation or ≥6 months since 
discontinuation or no prior endocrine therapy). HR+ was determined per the enrolling site 
and HER2 status was determined in a commercial laboratory in primary or metastatic sites 
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defined as either fluorescence in situ hybridization (FISH)-positive, 3+ staining by 
immunohistochemistry (IHC), or 2+ by IHC and confirmed HER2 FISH-positive.
17
 Ethical 
review of the study was performed by Hospital Vall d´Hebron IRB. No additional informed 
consent was required beyond the original informed consent of the clinical trial. 
 
Gene expression analysis 
 
 
A section of the formalin-fixed paraffin-embedded (FFPE) breast tissue was first examined 
with hematoxylin and eosin staining to confirm presence of invasive tumor cells and 
determine the tumor area. For RNA purification (Roche
®
 High Pure FFPET RNA isolation 
kit), ≥1–3 10 μm FFPE slides were used for each tumor specimen, and macrodissection was 
performed, when needed, to avoid normal breast tissue contamination.
18
 A minimum of 
 
∼150 ng of total RNA was used to measure the expression of 105 breast cancer-related genes 
and 5 housekeeping genes using the nCounter platform (Nanostring Technologies, Seattle, WA, 
US).
19
 Data were log base 2 transformed and normalized using 
 
5 housekeeping genes (ACTB, MRPL19, PSMC4, RPLP0, and SF3A1). Samples with ≤10 
counts in ≥50% of the genes were removed. Raw gene expression data will be deposited in 
Gene Expression Omnibus. 
 
Sample data and PAM50 intrinsic subtyping 
 
 
Of the 1286 tumor samples, 916 were profiled and 821 meet the minimum criteria for 
further analysis (eFigures 1 and 2). Intrinsic subtyping (Luminal A, Luminal B, HER2E, 
Basal-like and Normal-like) was performed using the research-based PAM50 intrinsic 
subtype predictor as previously described.
7,18
 Proper normalization was evaluated by a 
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principal component loading plot (eFigure 3). PAM50 subtyping was performed at the 
Translational Genomic Group at VHIO blinded from clinical data. 
 
Statistical analysis 
 
 
Estimates of PFS and overall survival (OS) were from Kaplan–Meier curves and tests of 
differences by log-rank test. Univariable and multivariable Cox-regression analyses were 
used to test the independent prognostic significance of each variable. To test the prognostic 
contribution of the PAM50 subtypes, changes in likelihood ratio (LR) values (χ2) were 
used to measure and compare the relative amount of additional prognostic information of 
one variable/score compared with another. To test the predictive value of the PAM50 
subtypes, interaction tests between PAM50 subtypes and treatment for PFS were evaluated 
in uni- and multivariable models. Proportional-hazards assumption was tested on the basis 
of Schoenfeld residuals. A 2-sided P < 0.05 was used as the threshold for statistical 
significance. 
 
Results 
 
 
Clinical-pathological characteristics and subtype distribution 
 
 
The clinical-pathological characteristics of the 821 patients with subtype data were well-
balanced compared with the patients included in the original study (eTable 1). The median 
age was 62 years, 86% of the patients had visceral disease, 644 (80%) had HER2-negative 
tumors, 157 (20%) had HER2+ disease and 73% had relapsed ≥6 months since 
discontinuation of anti-estrogen therapy or not received prior endocrine therapy. Similar to 
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the original results, lapatinib showed a significant PFS benefit in HER2+ disease but not 
in HER2-negative disease (eFigure 4). 
 
In both HER2-negative and HER2+ disease, all breast cancer intrinsic subtypes were 
identified albeit with different proportions (Table 1). Compared with HER2-negative 
disease, HER2+ disease had a lower proportion of Luminal A tumors (27% vs 52%) and a 
higher proportion of HER2E tumors (29% vs 3%). The proportion of Luminal B and Basal-
like tumors remained similar in both HER2 groups (29% vs 30% and 4% vs 3%, 
respectively). No significant differences in the distribution of the intrinsic subtypes were 
identified based on number of metastases, type of metastases and treatment arm. 
Interestingly, a significant increase in the proportion of non-luminal subtypes (17% vs 9%, 
 
P<0.001), mostly HER2E (70.6%), was observed in patients that relapsed during adjuvant 
endocrine therapy or within 6 months of discontinuation compared with those that never 
received or relapsed at least 6 months after completing adjuvant endocrine therapy (data not 
shown). 
 
Prognosis within HER2-negative disease 
 
 
Survival data were available for 644 patients with HER2-negative disease (eFigure 5). 
Compared with the Luminal A subtype, the other subtypes showed a significantly worse 
PFS (Figure 1A) independently of other clinical-pathological variables (Table 2). When 
other clinical-pathological variables were held constant, patients with Luminal B, HER2E 
and Basal-like subtypes had a 1.457, 2.873, and 2.258 times higher risk of tumor 
progression, respectively. Median PFS differed across the intrinsic subtypes: Luminal A 
(16.85 months, 95% confidence interval [CI]: 14.09–19.9), Luminal B (10.97 months, 95% 
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CI: 9.56–13.6), HER2E (4.67 months, 95% CI: 2.73–10.8) and Basal-like (4.14 months, 
95% CI: 2.53–13.8). Intrinsic subtype added more prognostic information regarding PFS 
 
than any of the other clinical-pathological variables evaluated in the model (LR 2 = 31.15; 
 
P<0.0001) (eTable 2). The second and third most important prognostic variables were prior 
 
endocrine therapy (LR 2 = 27.842; P<0.0001) and number of metastases (LR 2 = 15.377; 
 
P<0.0001). Interestingly, visceral versus nonvisceral disease did not provide independent 
 
prognostic information (LR 2 = 1.512; P=0.22). 
 
 
Similar results were observed in OS despite only 37.6% of patients with an event (Figure 
1B and eTable 3). Compared with patients with a Luminal A subtype, patients with a 
Luminal B, HER2E and Basal-like subtype had a 1.518, 2.528, and 2.338 times higher risk 
of death, respectively, when other clinical-pathological variables were held constant. 
Median OS differed across the intrinsic subtypes: Luminal A (45 months, 95% CI: 41–NA), 
Luminal B (37 months, 95% CI: 31–42), HER2E (16 months, 95% CI: 10–NA) and Basal-
like (23 months, 95% CI: 12-NA). Intrinsic subtype added more prognostic information 
 
regarding OS when added to the other clinical-pathological variables (LR 2 = 20.641; 
 
P<0.001) than any other variable evaluated (eTable 4), except prior endocrine therapy (LR 
 
2 = 25.686; P<0.0001). The third most important prognostic variable regarding OS was 
 
performance status (LR 2 = 14.426; P<0.001). 
 
 
Prognosis within HER2+ disease 
 
 
Survival data were available for 157 patients with HER2+ disease (Figure 1C). Compared 
with the Luminal A subtype, the other subtypes showed a worse PFS independently of 
other clinical-pathological variables (Table 3). When other clinical-pathological variables 
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were held constant, patients with a Luminal B, HER2E, and Basal-like had a 1.471, 1.818, and 
4.799 times higher risk of tumor progression, respectively. Median PFS differed across the 
intrinsic subtypes: Luminal A (11.07 months, 95% CI: 5.72–16.95), Luminal B (5.55 months, 
95% CI: 3.02–8.25), HER2E (4.37 months, 95% CI: 2.83–8.64), and Basal-like (3.58 months, 
95% CI: 2.27–NA). Intrinsic subtype added more prognostic information 
 
regarding PFS when added to the other clinical-pathological variables (LR 2 = 12.328; 
 
P=0.02) than any other variable evaluated (eTable 5). The second and third most important 
 
prognostic variables regarding PFS were lapatinib treatment (LR 2 = 6.626; P=0.01) and 
 
performance status (LR 2 = 5.339; P=0.02). 
 
 
In terms of OS, similar results were observed (Figure 1D and eTable 6 and 7). Compared 
with patients with a Luminal A subtype, patients with a Luminal B, HER2E, and Basal-like 
subtype had a 1.547, 1.913, and 2.919 times higher risk of death, respectively. Overall, 
median OS differed across the intrinsic subtypes: Luminal A (not reached), Luminal B 
 
(32 months, 95% CI: 21–NA), HER2E (28 months, 95% CI: 17–NA) and Basal-like 
(19 months, 95% CI: 9–NA). Intrinsic subtype added more prognostic information 
 
regarding OS when added to the other clinical-pathological variables (LR 2 = 9.955; 
 
P=0.04) than any other variable evaluated (eTable 7). The second and third most important 
 
prognostic variables regarding OS were prior endocrine therapy (LR 2 = 7.996; P=0.005) 
 
and number of metastases (LR 2 = 7.187; P=0.007). 
 
 
Benefit of lapatinib 
 
 
The effect of lapatinib on PFS in HER2-negative disease was evaluated within each 
intrinsic subtype (Figure 2). Among the different subtypes, only the HER2E showed a 
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significant benefit from lapatinib in univariate (6.49 month median PFS with lapatinib vs 
2.60 month median PFS with placebo; hazard ratio = 0.238, 95% CI: 0.066–0.863; P=0.03) 
and multivariate (lapatinib vs placebo hazard ratio = 0.040, 95% CI: 0.04–0.395; P=0.006) 
analyses. The interaction test between HER2E and treatment was significant in univariate 
(P=0.02) and multivariate analyses (P=0.006). 
 
The effect of lapatinib on PFS in HER2+ was evaluated within each intrinsic subtype 
(eFigure 6). All subtypes seemed to benefit to some degree from lapatinib by looking at the 
estimate of the hazard ratio. The interaction tests between each subtype and treatment were 
not statistically significant (data not shown). 
 
HER2 IHC and FISH in HER2E/HER2-negative tumors 
 
 
Fifty percent (8/16) of samples identified in the EGF30008 trial as clinically 
HER2E/HER2-negative showed either a lack of HER2 expression by IHC or a +1 score 
(eTable 8). FISH determination in 6 of these samples showed a HER2/CEP17 ratio of ≤1.6 
(eTable 9). Among the other 8 HER2E/HER2-negative cases with an IHC 2+ score, 6 
were tested for HER2 gene amplification; all showed a HER2/CEP17 ratio of ≤1.6 (Table 
S8). Thus, the HER2E/HER2-negative cases did not show evidence of HER2 gene 
amplification. 
 
Discussion 
 
 
To our knowledge, this is the first report to evaluate the prognostic and predictive abilities 
of breast cancer intrinsic molecular subtypes in postmenopausal patients with HR+ 
metastatic disease treated with endocrine therapy +/- lapatinib in the first-line setting. 
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Specifically, our results reveal that (1) all intrinsic molecular subtypes are identified within 
HER2-negative and HER2+ diseases, albeit with different proportions; (2) Intrinsic subtype is 
the most important and independent prognostic factor in this setting, even within HER2+ 
disease; (3) 95% of patients with Luminal A/HER2-negative disease experience long PFS 
periods of 14.1–19.9 months with letrozole therapy; (4) Patients with HER2E/HER2-negative 
disease treated with letrozole therapy may benefit from the addition of lapatinib. 
 
The optimal systemic treatment strategy for newly diagnosed patients with HR+ 
advanced/metastatic breast cancer is currently unknown. National Comprehensive Cancer 
Network or European School of Oncology-European Society of Medical Oncology 2nd 
international consensus guidelines for advanced breast cancer
20,21
 recommend starting 
with endocrine therapy but base the decision on clinical parameters such as amount of 
tumor burden, age, performance status, disease-free interval, or previous therapies in the 
adjuvant setting. However, HR+ disease is clinically and biologically heterogeneous and 
thus there is an urgent need to identify robust prognostic and/or predictive tumor-based 
biomarkers to be included with other clinical variables considered in patient management 
and therapy selection decisions. For example, no predictive biomarker exists to date for 
novel drugs such as CDK4/6 and PI3K/mTOR inhibitors that are currently being 
incorporated earlier in the treatment of HR+/HER2-negative metastatic disease in 
combination with endocrine therapy. 
 
A limited number of studies have evaluated the prognostic value of single pathology-based 
biomarkers for predicting outcome in the first-line HR+ metastatic breast cancer setting 
following endocrine therapy.
22-25
 For example, Delpech and colleagues
22
 showed that high 
baseline Ki67 expression in 241 estrogen receptor positive (ER+) primary breast cancers 
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correlated with lower clinical benefit and time to progression on first-line endocrine 
therapy. Similar results with Ki67 were obtained by Yamashita and colleagues in a series of 
73 cases.
23
 Moreover, a study of the Southwest Oncology Group evaluated the prognostic 
ability of progesterone receptor (PR) expression in 398 patients with ER+ metastatic breast 
cancer treated with tamoxifen
24
 and showed that elevated PR levels in the primary tumor 
significantly and independently correlated with increased probability of response to 
tamoxifen, longer time to treatment failure and OS. Finally, Rocca and colleagues
25
 
showed that high Ki67 or low PR expression measured in metastatic tissue of 135 patients 
with HR+ disease was correlated with lower time to tumor progression following first-line 
endocrine therapy. Overall, these data are concordant with our results since proliferation 
and estrogen-regulation are two key biological features that distinguish Luminal A from 
non-Luminal A molecular subypes.
26
 
 
Non-luminal intrinsic subtypes (ie, HER2E and Basal-like) represent 3–10% of all HR+ 
breast cancers.
6-8
 In patients with HR+ disease treated with 5 years of adjuvant tamoxifen 
only, HER2E and Basal-like subtypes had very poor disease-free survival.
9
 Concordant 
with this finding, both subtypes had the lowest relative decrease in Ki-67 either at 2 weeks 
or at 4–6 months following neoadjuvant endocrine therapy.
10,11
 In terms of 
chemosensitivity, Jimenez and colleagues recently evaluated the pathological complete 
response (pCR) rates of the intrinsic subtypes within 180 patients with HR+/HER2-
negative disease following anthracycline/taxane-based neoadjuvant chemotherapy.
27
 
 
Interestingly, patients with HR+/Basal-like disease, which represented 7.7% of the 
population, achieved a pCR rate of 50%, followed by patients with Luminal B, HER2E, 
and Luminal A tumors who achieved a pCR rate of 20%, 14.3%, and 9.3%, respectively. 
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Overall, these data, together with our results showing a median PFS of 4.5 months in non-
luminal subtypes within HR+/HER2-negative disease, suggest that molecular subtype may 
better represent tumor behavior in the setting of cytotoxic or endocrine therapy than clinical 
hormone receptor assays. 
 
The observation that patients with HER2E/HER2-negative tumors benefit from lapatinib is 
intriguing. Our prior work has revealed that HER2E/HER2-negative tumors have similar 
genomic and genetic alterations as HER2E/HER2+ tumors except for the HER2 amplicon, 
which is only overexpressed/amplified in those HER2E tumors that are HER2+.
28
 Similar 
results were obtained in the EGF30008 study when the HER2 gene expression was 
evaluated across the intrinsic subtypes based on clinical HER2 status (eFigure 7). Thus, 
the efficacy of lapatinib in the group of patients with HER2-negative/HER2E disease 
might be due to EGFR inhibition rather than HER2 inhibition although this will require 
further investigation. 
 
The present study has several limitations. First, this is an unplanned retrospective analysis 
of a prospective clinical trial. To minimize bias, we were able to profile almost 2 out of 3 
tumor samples from the original population, and the population representative of this subset 
had a similar distribution of clinical-pathological variables and a similar outcome behavior 
as the original study population. In addition, the laboratory that performed and reported the 
gene expression results for each sample was blinded from clinical data. Secondly, the vast 
majority of profiled samples from this dataset come from primary tumors rather than 
metastatic tumor. Although we cannot predict the findings if the analysis would have been 
done on metastatic samples only, the reality is that metastatic tissues are not always 
available in clinical practice and thus a biomarker derived from primary tumors is of value, 
15 
 
especially if this biomarker remains stable during tumor progression such as the intrinsic 
subtypes.
12
 However, further studies are needed to determine the concordance of 
intrinsic subtyping in primary versus metastatic tissues and the stability of subtype 
during or after therapy. Finally, in the EGF30008 clinical study, HER2 testing was 
performed by a high-volume, commercial laboratory to determine HER2 status using 
standardize testing methods in a single laboratory. Additionally, HER2 status was 
evaluated by an academic reference laboratory in a limited number of cases from the 
EGF30008 study population, revealing 93% concordance (eTable 10).
16,17
 
 
To conclude, HR+ disease is biologically heterogeneous and intrinsic subtypes are strongly 
prognostic in a first-line metastatic setting. HR+/HER2- disease with a HER2E profile may 
benefit from lapatinib. The clinical value of intrinsic subtyping in HR+ metastatic breast 
cancer warrants further investigation, but patients with Luminal A/HER2-negative 
metastatic disease might be good candidates for letrozole monotherapy in the first-line 
setting regardless of visceral disease and number of metastases, whereas patients with 
HER2E/HER2-negative or Basal-like/HER2-negative subtypes need other treatment 
strategies such as chemotherapy or novel targeted drugs. 
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 Tables 
 
 
 
Table 1. Distribution of the intrinsic subtypes within the entire population and within HER2-negative and HER2-positive 
 
subpopulations. HER2, human epidermal growth factor receptor 2. 
 
 
  All patients
a
  HER2-negative  HER2-positive 
Subtype N %  N %  N % 
Luminal A  382 47  335 52  42 27 
Luminal B 244 30 196 30 46 29 
HER2E  61 7  16 3  45 29 
Basal-like 28 3 21 3 6 4 
Normal-like  106 13  76 12  18 11 
 
a
HER2 status was unknown in 20 patients. 
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 Table 2. Cox model progression-free survival analysis within HER2-negative
a
 disease (n=644). 
 
    Univariate analysis      Multivariable analysis   
 
 
Variables 
 
HR 
Lower Upper  P-  
HR 
 
Lower 95% 
 
Upper 95% 
 P- 
 
  
95% 95% 
  
value 
    
value 
 
             
 
                  
 Lapatinib vs placebo  0.925 0.766 1.118   0.42  0.905  0.745  1.100  0.32 
 
 Prior endocrine therapy                
 
 <6 months vs ≥6 months or none 1.769 1.429 2.190  <0.001 1.903 1.513 2.394 <0.001 
 
 Performance status 1 vs 0 1.321 1.091 1.598  0.004 1.373 1.126 1.675 0.002 
 
 Visceral vs no visceral 1.120 0.837 1.451  0.49 0.891 0.656 1.209 0.46 
 
 ≥3 sites vs <3 sites 1.427 1.180 1.725  <0.001 1.537 1.238 1.907 <0.001 
 
 Age 0.994 0.984 1.004  0.21 1.005 0.985 1.005 0.35 
 
 FFPE metastatic vs primary 0.753 0.564 1.006  0.06 0.677 0.500 0.916 0.012 
 
                  
 PAM50 subtype                
 
 Luminal A  1.000 - -   -  1.000  -  -  - 
 
 Luminal B  1.468 1.183 1.822   <0.001  1.457  1.168  1.818  <0.001 
 
 Basal-like  2.510 1.548 4.071   <0.001  2.258  1.367  3.732  0.001 
 
 HER2E  3.193 1.814 5.620   <0.001  2.873  1.600  5.161  <0.001 
 
 Normal-like  1.784 1.327 2.397   <0.001  1.871  1.389  2.522  <0.001 
 
                 
  
a
HER2 status was determined in a commercial laboratory in primary or metastatic sites defined as either FISH-positive, 3+ staining by IHC, or 
2+ by IHC and confirmed HER2 FISH-positive. 
 
FFPE, formalin-fixed paraffin-embedded; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HR, hazard 
ratio; IHC, immunohistochemistry. 
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 Table 3. Cox model progression-free survival analysis within HER2-positive disease
a
 (n=157). 
 
     Univariate analysis     Multivariable analysis  
 
 
Variables 
 
HR 
 
Lower 95% 
 
Upper 95% 
 P-  
HR 
Lower Upper P- 
 
     
value 
 
95% 95% 
 
value 
 
            
 
                 
 Lapatinib vs placebo  0.697 0.494  0.984  0.04  0.614 0.423 0.889  0.01 
 
 Prior endocrine therapy               
 
 <6 months vs ≥6 months or none 1.257 0.884 1.787 0.20 1.296 0.854 1.968  0.22 
 
 PS 1 vs 0 1.486 1.049 2·103 0.03 1.543 0.584 1.729  0.02 
 
 Visceral vs no visceral 1.147 0.705 1.867 0.58 1.005 1.068 2.230  0.99 
 
 ≥3 sites vs <3 sites 1.310 0.923 1.858 0.13 1.601 1.056 2.427  0.03 
 
 Age 0.985 0.965 1.005 0.13 0.983 0.962 1.004  0.12 
 
 FFPE metastatic vs primary 1.020 0.563 1.850 0.95 1.246 0.617 2.515  0.54 
 
                 
 PAM50 subtype               
 
 Luminal A  1.000 -  -  -  1.000 - -  - 
 
 Luminal B  1.667 1.023  2.718  0.04  1.471 0.863 2.505  0.16 
 
 Basal-like  4.591 1.853  11.378  0.001  4.799 1.885 12.217  0.001 
 
 HER2E  1.922 1.189  3.107  0.008  1.818 1.116 2.960  0.02 
 
 Normal-like  2.356 1.302  4.265  0.005  1.762 0.938 3.310  0.08 
 
                  
a
HER2 status was determined in a commercial laboratory in primary or metastatic sites defined as either FISH-positive, 3+ staining by IHC, or 
2+ by IHC and confirmed HER2 FISH-positive. 
 
FFPE, formalin-fixed paraffin-embedded; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HR, hazard 
ratio; IHC, immunohistochemistry. 
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Figure 1. Survival outcomes based on intrinsic subtype. (A) PFS in HER2-negative 
disease; (B) OS in HER2-negative disease; (C) PFS in HER2-positive disease; (D) OS in 
HER2-positive disease. Normal-like cases have been excluded in this plot since they are not 
considered a tumor subtype
4,5
. HER2, human epidermal growth factor receptor 2; OS, 
overall survival; PFS, progression-free survival. The results shown here are heedless of 
treatment arm (with or without lapatinib). 
  
Figure 2. Effect of lapatinib within each intrinsic subtype in the HER2-negative population 
of the EGF30008 trial. (A) Luminal A; (B) Luminal B; (C) HER2E; (D) Basal-like. 
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